Dr. Scot Niglio

Dr. Scot Niglio, MD, is a genitourinary medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), where he specializes in the diagnosis and treatment of genitourinary cancers, with a particular focus on urothelial carcinoma, including cancers of the bladder, urethra, ureter, and renal pelvis. He also has extensive experience treating rare genitourinary cancers. Dr. Niglio sees patients at the David H. Koch Center for Cancer Care at MSK and at Memorial Sloan Kettering Westchester locations, working closely within a multidisciplinary team that includes surgeons and radiation oncologists to deliver comprehensive, individualized care. When appropriate, he offers patients access to clinical trials as part of their treatment planning.

Dr. Niglio's research centers on developing new treatments for genitourinary cancers, with a strong emphasis on immunotherapy. He has contributed to numerous peer-reviewed publications and has participated in multiple clinical trials investigating therapies for bladder and urinary tract cancers. His contributions were recognized with a National Institutes of Health Director's Award for his work as part of the phase 1 team that developed an immunotherapy combination now approved by the FDA as a first-line therapy for advanced kidney cancer.

His path to oncology was shaped by deeply personal experiences. Growing up in a cancer cluster where childhood cancer rates were elevated and linked to chemicals leaching into local water supplies, he developed an early interest in environmental factors and cancer research. His father's own bladder cancer diagnosis during his residency further guided his focus toward genitourinary oncology and reinforced his belief in the importance of ongoing, transparent communication with patients and families. He takes a deliberate approach to patient education, spreading information across multiple visits and welcoming follow-up questions, recognizing that patients cannot absorb everything at once.